This New Medicare Pilot Program Offers GLP-1s For $50 A Month. Here’s What You Need To Know
Medicare has launched a new pilot program called Bridge that allows eligible beneficiaries to access GLP-1 obesity drugs from Novo Nordisk and Eli Lilly for $50 per month, a dramatic reduction from hundreds of dollars. However, the program faces implementation challenges and is only guaranteed through the end of 2027, creating uncertainty for patients starting long-term therapies.
Summary
Starting this week, millions of eligible Medicare patients gain access to GLP-1 obesity drugs through a new federal pilot program called Bridge, marking a significant shift in Medicare policy. Traditionally, Medicare has barred coverage of medications prescribed solely for obesity, but this program creates a temporary pathway for coverage. Eligible beneficiaries must meet certain requirements, including a BMI over 35 and the presence of certain obesity-related conditions, and can access these medications for a $50 monthly copay instead of the typical hundreds of dollars per month. This move could potentially reach as many as 20 million new patients according to Novo Nordisk and Eli Lilly's estimates, with officials expecting several million beneficiaries to enroll immediately. The program addresses a significant access gap for older Americans who have been unable to afford these popular weight loss drugs. However, the rollout faces practical challenges. Doctors must submit prior authorization requests to confirm patient eligibility before coverage is approved, and physicians are concerned that an influx of new patients could strain already busy clinics and pharmacies. More critically, the coverage is not permanent—unless the Trump administration extends or replaces the program, Bridge coverage is scheduled to expire by the end of 2027, and any permanent changes would require congressional approval. This creates a significant risk for patients who will begin long-term obesity therapies without knowing whether coverage will continue beyond 2027.
Key Insights
- GLP-1 obesity drugs have cost hundreds of dollars per month, making them out of reach for most older Americans on Medicare until this week's program launch
- The Bridge program represents a major shift because Medicare has traditionally barred coverage of medications prescribed solely for obesity
- Novo Nordisk and Eli Lilly estimate the program could reach as many as 20 million eligible patients, with several million expected to enroll immediately
- Physicians warn that a wave of new patients could put additional pressure on already busy clinics and pharmacies over the next couple of months
- The coverage through Bridge is scheduled to expire by the end of 2027 unless the Trump administration extends it, and permanent changes would require congressional approval
Topics
Transcript
[0:00] Popular weight loss drugs have remained out of reach for most older Americans in Medicare for years. That's because GLP-1s can cost hundreds of dollars per month, but that changes this week. Starting Wednesday, millions of eligible Medicare patients can access GLP-1 obesity drugs >> [music] >> from Novo Nordisk and Eli Lilly for a copay of just $50 per month. It's a major shift for a federal program that has traditionally barred coverage of medications prescribed solely for obesity. So, what happened? Well, there's a new Medicare pilot program called Bridge that's creating a temporary pathway for coverage. Patients [0:31] who meet [music] certain requirements, including those with a BMI of over 35 and people with certain obesity-related…
Full transcript available for MurmurCast members
Sign Up to AccessMore from CNBC
The rise, reinvention and uncertain future of Nvidia without Jensen Huang
Nvidia founder Jensen Huang has been removed as CEO amid allegations of multiple affairs, including with direct reports, and connections to Alice Wong, who may be a Chinese spy involved in distributing AI chips across Southeast Asia. The scandal represents the company's biggest crisis in its 33-year history, occurring during a period of strict U.S. export controls on advanced chips to China.
Could Democratic Gains Bring Tariff Relief For Canada?
Following Democrats' 2026 midterm victories, Canadian investors anticipate potential tariff relief, but progress will likely be slow given President Trump's remaining two years in office and the complexity of trade negotiations. While some sectors like steel, lumber, and agriculture could benefit from reduced tariffs, Rust Belt Democrats and security concerns may limit the scope of relief.
Nvidia In Crisis: The Rise Of Jensen Huang’s Empire At The Center Of The AI Boom
This documentary examines Nvidia's rise to dominance in AI computing and the recent crisis surrounding founder Jensen Huang's resignation following allegations of affairs and potential involvement with a figure connected to Chinese AI chip diversion schemes. The narrative explores how Huang built Nvidia from a graphics card startup in 1993 into a $150+ billion company at the center of the AI boom, while also detailing geopolitical risks, export control complications, and questions about the company's future without its iconic founder.
How Democrats Won Back Union Voters
Democrats have dramatically reversed declining support among union voters, winning union households by 22 percentage points in the 2026 midterms compared to just 8 points in 2024. This turnaround was driven by aggressive union organizing efforts and increased voter enthusiasm, though questions remain about sustaining this advantage in future presidential elections.
Why Cheaper Car Sales Have Fallen
The auto industry is experiencing a crisis in affordable car sales despite stronger demand for lower-priced vehicles, driven by record-high financing terms, loan amounts exceeding $1,000 monthly, and shrinking inventory in the compact car segment. Entry-level buyers are increasingly priced out of the market as manufacturers prioritize profitable vehicles over affordable options and offer fewer incentives.